CLAIMS

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

wherein:

X^1 is N or CH;

R^1 is $-P(O)(OH)_2$;

R^2 is hydrogen, $-(C_{1-6})$alkyl, $-NR^aR^b$, halo, or $-(C_{1-6})$haloalkyl;

each of R^3 and R^4 is independently hydrogen, halo, cyano, $-NR^aR^b$, $-(C_{1-6})$alkyl, $-(C_{1-6})$haloalkyl, $-O-(C_{1-6})$alkyl, or $-O-(C_{1-6})$haloalkyl;

each R^5 is independently halo, $-(C_{1-6})$alkyl, $-O(C_{1-6})$alkyl, or $-O(C_{1-6})$haloalkyl;

R^6 is hydrogen or $-(C_{1-6})$alkyl;

R^7 is hydrogen, $-(C_{1-6})$alkyl, halo, or $-(C_{1-6})$haloalkyl;

each of R^a and R^b is independently hydrogen or $-(C_{1-6})$alkyl; and

n is 0, 1, or 2.

2. The compound according to claim 1, wherein X^1 is N.
3. The compound according to claim 1, wherein X^1 is CH.
4. The compound according to any one of claims 1-3, wherein R^2 is $-(C_{1-6})$alkyl.
5. The compound according to any one of claims 1-4, wherein each of R^3 and R^4 is independently hydrogen, halo, or $-(C_{1-6})$haloalkyl.
6. The compound according to claim 5, wherein each of R^3 and R^4 is hydrogen, -Cl, or $-CF_3$.
7. The compound according to any one of claims 1-3, wherein one of R^3 and R^4 is hydrogen and the other of R^3 and R^4 is halo or $-(C_{1-6})$haloalkyl.
8. The compound according to claim 7, wherein one of R^3 and R^4 is hydrogen and the other of R^3 and R^4 is -Cl or $-CF_3$.

9. The compound according to any one of claims 1-8, wherein each R^5 is independently halo or -O(C_{1-6})haloalkyl.
10. The compound according to claim 9, wherein each R^5 is independently -F or -OCF_3.
11. The compound according to any one of claims 1-10, wherein R^6 is –(C_{1-6})alkyl.
12. The compound according to claim 11, wherein R^6 is -CH_3, -CH_2CH_3, or -$CH(CH_3)_2$.
13. The compound according to claim 1, wherein:

X^1 is N;

R^1 is -$PO(OH)_2$;

R^2 is -CH_3;

one of R^3 and R^4 is hydrogen and the other of R^3 and R^4 is halo or –(C1-6)haloalkyl;

R^5 is halo or –O(C_{1-6})haloalkyl;

R^6 is –(C_{1-6})alkyl;

R^7 is hydrogen; and

n is 1.

14. The compound according to any one of claims 1 to 13, being a pharmaceutically acceptable salt of the compound of formula (I), wherein:

R^1 is -$P(O)(OH)O^-M^+$, -$PO(O^-)_2$•$2M^+$, or -$PO(O^-)_2$•D^{2+};

each M^+ is independently a pharmaceutically acceptable monovalent cation; and

D^{2+} is a pharmaceutically acceptable divalent cation.

15. A compound selected from the group consisting of:

(5-(1-(4-Fluoro-2-methylphenyl)-4-oxo-6-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl)-6-methyl-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate;

(5-(1-(4-fluoro-2-methylphenyl)-4-oxo-7-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl)-6-methyl-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate;

(5-(6-chloro-1-(4-fluoro-2-methylphenyl)-4-oxo-1,4-dihydroquinazolin-3(2H)-yl)-6-methyl-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate; and

(6-methyl-5-(1-(2-methyl-4-(trifluoromethoxy)phenyl)-4-oxo-6-(trifluoromethyl)-1,4-dihydropyrido[2,3-d]pyrimidin-3(2H)-yl)-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate,

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound as defined in any one of claims 1-15, and a pharmaceutically acceptable excipient.
17. The pharmaceutical composition according to claim 16, formulated for intravenous administration.
18. A compound or pharmaceutically acceptable salt thereof or tautomer thereof according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 16 or claim 17 for use in therapy.
19. A compound or pharmaceutically acceptable salt thereof or tautomer thereof according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 16 or claim 17 for use in treatment of pain or a pain-associated disease, disorder, or condition.
20. The compound or pharmaceutically acceptable salt thereof or tautomer thereof, or pharmaceutical composition according to claim 19, wherein the pain is acute pain or chronic pain.
21. The compound or pharmaceutically acceptable salt thereof or tautomer thereof, or pharmaceutical composition according to claim 19, wherein the pain or pain-associated disease, disorder, or condition is pain caused by trauma; pain caused by iatrogenic medical or dental procedures; or pre-operative or post-operative associated pain.
22. The compound or pharmaceutically acceptable salt thereof or tautomer thereof, or pharmaceutical composition according to claim 19, wherein the pain or pain-associated disease, disorder, or condition is neuropathic pain, nociceptive pain, inflammatory pain, musculoskeletal pain, visceral pain, or idiopathic pain.
23. The compound or pharmaceutically acceptable salt thereof or tautomer thereof, or pharmaceutical composition according to claim 19, wherein the pain or pain-associated disease, disorder or condition is neuropathic pain or chronic neuropathic pain selected from small fiber neuropathy, small fiber-mediated diabetic neuropathy, idiopathic small fiber neuropathy, painful diabetic neuropathy or polyneuropathy.
24. The compound or pharmaceutically acceptable salt thereof or tautomer thereof, or pharmaceutical composition according to claim 19, wherein the pain or pain associated disease, disorder, or condition is inflammatory pain selected from osteoarthritis, chronic osteoarthritis pain, or chronic inflammatory demyelinating polyneuropathy.
25. A compound or pharmaceutically acceptable salt thereof or tautomer thereof according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 16 or claim 17 for use in treatment of atrial fibrillation.